|
1
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Spira A and Ettinger DS: Multidisciplinary
management of lung cancer. N Engl J Med. 350:379–392. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lanaya H, Natarajan A, Komposch K, Li L,
Amberg N, Chen L, Wculek SK, Hammer M, Zenz R, Peck-Radosavljevic
M, et al: EGFR has a tumour-promoting role in liver macrophages
during hepatocellular carcinoma formation. Nat Cell Biol.
16:972–981. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pao W and Chmielecki J: Rational,
biologically based treatment of EGFR-mutant non-small-cell lung
cancer. Nat Rev Cancer. 10:760–774. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pirker R, Pereira JR, von Pawel J,
Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE,
Paz-Ares L, Störkel S, et al: EGFR expression as a predictor of
survival for first-line chemotherapy plus cetuximab in patients
with advanced non-small-cell lung cancer: Analysis of data from the
phase 3 FLEX study. Lancet Oncol. 13:33–42. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gao SP, Mark KG, Leslie K, Pao W, Motoi N,
Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B and Bromberg
JF: Mutations in the EGFR kinase domain mediate STAT3 activation
via IL-6 production in human lung adenocarcinomas. J Clin Invest.
117:3846–3856. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F,
Ha SJ, Soo RA, Christensen JG, Lee JH and Cho BC: Activation of
IL-6R/JAK1/STAT3 signaling induces de novo resistance to
irreversible EGFR inhibitors in non-small cell lung cancer with
T790M resistance mutation. Mol Cancer Ther. 11:2254–2264. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li J, Lan T, Zhang C, Zeng C, Hou J, Yang
Z, Zhang M, Liu J and Liu B: Reciprocal activation between
IL-6/STAT3 and NOX4/Akt signaling promotes proliferation and
survival of non-small cell lung cancer cells. Oncotarget.
6:1031–1048. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abulaiti A, Shintani Y, Funaki S, Nakagiri
T, Inoue M, Sawabata N, Minami M and Okumura M: Interaction between
non-small-cell lung cancer cells and fibroblasts via enhancement of
TGF-β1 signaling by IL-6. Lung Cancer. 82:204–213. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen J, Lan T, Zhang W, Dong L, Kang N,
Zhang S, Fu M, Liu B, Liu K and Zhan Q: Feed-forward reciprocal
activation of PAFR and STAT3 regulates epithelial-mesenchymal
transition in non-small cell lung cancer. Cancer Res. 75:4198–4210.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang FQ, Yang WT, Duan SZ, Xia YC, Zhu RY
and Chen YB: JAK2 inhibitor TG101348 overcomes erlotinib-resistance
in non-small cell lung carcinoma cells with mutated EGF receptor.
Oncotarget. 6:14329–14343. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Y, Xu Y, Ji W, Li X, Sun B, Gao Q and
Su C: Anti-tumor activities of matrine and oxymatrine: Literature
review. Tumour Biol. 35:5111–5119. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang LP, Jiang JK, Tam JW, Zhang Y, Liu
XS, Xu XR, Liu BZ and He YJ: Effects of matrine on proliferation
and differentiation in K-562 cells. Leuk Res. 25:793–800. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu X, Zhu Z, Jiang L, Sun X, Jia Z, Qian
S, Li J and Ma L: Matrine increases NKG2D ligand ULBP2 in K562
cells via inhibiting JAK/STAT3 pathway: A potential mechanism
underlying the immunotherapy of matrine in leukemia. Am J Transl
Res. 7:1838–1849. 2015.PubMed/NCBI
|
|
18
|
Lin W, Zhang JP, Hu ZL and Qian DH:
Inhibitory effect of matrine on lipopolysacchride-induced tumor
necrosis factor and interleukin-6 production from rat Kupffer
cells. Yao Xue Xue Bao. 32:93–96. 1997.(In Chinese). PubMed/NCBI
|
|
19
|
Zhang Y, Wang S, Li Y, Xiao Z, Hu Z and
Zhang J: Sophocarpine and matrine inhibit the production of
TNF-alpha and IL-6 in murine macrophages and prevent
cachexia-related symptoms induced by colon26 adenocarcinoma in
mice. Int Immunopharmacol. 8:1767–1772. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu X, Ye F, Xiong H, Hu DN, Limb GA, Xie
T, Peng L, Zhang P, Wei Y, Zhang W, et al: IL-1β induces IL-6
production in retinal Müller cells predominantly through the
activation of P38 MAPK/NF-κB signaling pathway. Exp Cell Res.
331:223–231. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thress KS, Paweletz CP, Felip E, Cho BC,
Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, et
al: Acquired EGFR C797S mutation mediates resistance to AZD9291 in
non-small cell lung cancer harboring EGFR T790M. Nat Med.
21:560–562. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jia Y, Yun CH, Park E, Ercan D, Manuia M,
Juarez J, Xu C, Rhee K, Chen T, Zhang H, et al: Overcoming
EGFR(T790M) and EGFR(C797S) resistance with mutant-selective
allosteric inhibitors. Nature. 534:129–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nan J, Du Y, Chen X, Bai Q, Wang Y, Zhang
X, Zhu N, Zhang J, Hou J, Wang Q and Yang J: TPCA-1 is a direct
dual inhibitor of STAT3 and NF-κB and regresses mutant
EGFR-associated human non-small cell lung cancers. Mol Cancer Ther.
13:617–629. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma L, Zhu Z, Jiang L, Sun X, Lu X, Zhou M,
Qian S and Jianyong L: Matrine suppresses cell growth of human
chronic myeloid leukemia cells via its inhibition of the
interleukin-6/Janus activated kinase/signal transducer and
activator of transcription 3 signaling cohort. Leuk Lymphoma.
56:2923–2930. 2015. View Article : Google Scholar : PubMed/NCBI
|
